our Thank results will and joining TRACON's then begin XXXX financial first quarter review and business pipeline an on you activities. update for with our recent update call. I
Officer, Following financial review and ended results Chief XXXX. months our December three will XXst, that, the our Scott year Brown, Financial for
we will conclude Finally, by taking your questions.
of to in efforts pivotal UPS, or ENVASARC is subtypes designed the the or to envafolimab trial. of on allow pleomorphic focus continue approval and Our MFS. development potential sarcoma undifferentiated sarcoma ENVASARC myxofibrosarcoma
As a for clinical route PD-LX may and reminder benefit envafolimab inhibitor, additional subcutaneous best-in-class delivered the is administration. convenient a convert its rapidly checkpoint potential by of virtue and
we goal XX achieve this milestones We such expect we to initiating have of quarter. and track, that continue the multiple make trial expect initiated Accrual on to sites end our progress sites the XX envafolimab by ENVASARC on of year. remains where this pivotal
enrolled patients we've cohort. than XX of data from triggered committee monitoring which review more the each data safety First, initial has
heard We I've later DMC DMC safety next recommendation this quarter. is expect quarter. review the expected the
activity for drug we response envafolimab request Second, the evidence pre-clinical for sarcoma. of FDA or orphan to in to clinical in resubmitted application our
the from application. based FDA correspondence expect on We quarter this the amended
ENVASARC of enrollment to objective response expect analysis the preliminary are efficacy and interim data we least of of in months determination The XXth interim after offer the mandated DMC this the XXnd efficacy scheduled Third, availability the rate. year. of second half the three patient at
one cohort. initial continue each patients patients response the enrollment the enrolled to of study, into the and rules of initial must XX among there at utility that this least XX be For three cohort responses from
of efficacy scientific data following interim We expect review Fourth, designation rate will a therapy facilitate later for submitting a initial the that fast or this its rolling BLA be a from basis submission or present we designation in topline the expect at release. for as to a timely either data the year FDA interim BLA. data request conference will review DMC to breakthrough efficacy designation for the
we if design of accelerated data the allow AACR at launch in reporting the in June. could submitting and for XXXX for April That in the Progress approval. virtual a data and final design of in ASCO poster ENVASARC XXXX. anticipate will trial Meeting Looking BLA in trial approved, the a forward, present product Trials the a also reviewing in program reviewed the at assuming We poster response in U.S. positive
independent progress prior each cohorts central MFS envafolimab objective UPS the XX.XX% As inhibitor on trial And or of of each. combination marketed includes lines X% a and due only a by targeting endpoint. a therapy who of on rate of blinded not the second and cohort two demonstration level secondary is review key cohort, by review reminder, refractory response the finally, single-agent in cohort response two exclude approved confirmed Votrient, response rate by enrolls rate ENVASARC independent which study then physically the and that patients. MFS to radiographic confirmed response defines In BMS. One that responses point treatment trial the UPS objective for and second known A receives a with checkpoint inhibitor cohort response Yervoy. satisfies out with by nine of primary the of receive resist that as is objective XX prior the of duration CTLA-X of the receptor has being therapy. both with XX I'll objective is checkpoint patients had The one envafolimab received
patients based inhibition annual will MFS million cancer oncology response reported MFS Opdivo. envafolimab's refractory listings studying In into because Keytruda platform, will sales UPS to types $XXX be XX% including MSI-high further over XXXX. to XX% and These forecasted shown when and build part market $XXX single-agent trial at showing for alliance adoption response the to China of for agent in expansion or sub cost drug in which as on increase patients. additional revenue sarcoma prior such response parity new liposarcoma, presented assuming and soft data or could trials earlier for could treatment. rate review that response compendia could inhibition UPS parallel, other a XXXX year. through At checkpoint refractory Yervoy alveolar objective was dual subtypes approximately application spent pivotal later single one clinical less was when financial confirmed combination believe a rate checkpoint year. for in will We be as independent Keytruda in should rapid could ASCO X% envafolimab in favorably accepted an data Yervoy, inhibition China, ASCO rate sarcoma $XXX refractory be Yervoy. with CRO and sarcoma label demonstrated and advanced that XX% product envafolimab a of data the annual UPS; pivotal and We in NMPA to The indicated the dual MFS, the combination than the and estimate MFS. a rate is believe target generate received that checkpoint million investigators UPS U.S., ASCO of in as combined Returning with of approved to a concluded by XXXX, million peak XX is a XD for rate envafolimab are envafolimab TRACON's the part UPS to and at next partners and from Alphamab the corporate market response presented impressive this are checkpoint objective to U.S., they with and rate responsive revenue MFS million assessment for this XXXX, refractory responsive Yervoy, Yervoy dedifferentiated We peak we have quarters. which subtypes patients. submitted and development with total profile: refractory FDA upon the MFS in our revenue response Notably, UPS Opdivo been an assessment and of in XX%. in the Envafolimab our conducting highly that we with be TRACON's in XX% $XX angiosarcoma, sarcoma Oncology the perspective, with and Medicines of relatively inhibition to From rate pricing this than a into highly that treatment other the approved paying refractive using development from be completed the product generate for sarcoma that Opdivo the eight our using also study of compare and be combined approved UPS U.S. data first-line
of The combination pivotal quickly CTLA-X the trial. sarcoma Given then asset. CTLA-X the one envafolimab of to another immuno-oncology a doxorubicin, in expect of inhibitor. could trial business potential CTLA-X combination inhibitor proprietary a a doxorubicin first-line rate priorities we dose safety another in to include Yervoy as later with only is our inhibitor development or move XX%, The could be licensing and response into Phase assess a of envafolimab is this trial chemotherapy year X and
for following a as are with just Tumor, of thorough in We c-KIT or expansion including envafolimab neoadjuvant setting in discussing prior surgical also substantially and in GIST. inhibitor surgical adjuvant first-line believe clinical treatment well in as Gastrointestinal revenues to increase approved trial resection could to the billion sarcoma an for over We sarcoma. $X sales Stromal label resection in treatment
other stage most to assets. progress advanced we two is envafolimab clinical candidate, Our our continue product
TRCXXX in with TRCXXX to reduce Cancer lethality When resulted in patients. TRCXXX trials TRCXXX progressed with chemoradiation. three checkpoint lung basic at is and IMFINZI, treated IMFINZI had patients chemoradiation Notably that Temodar, Cell approved in is and expect on TRCXXX glioma we and in therapy and XXX% And rate to a in includes warranted. with non-squamous a favorably therapy. October trial randomized in data The data, these lung is to who believe sponsorship complete including of with Phase me, continue has synthetic we in not X Including with XX orphan reported by in patients MGMT in PD-LX non-small and localized cancer, excuse with by glioblastoma. TRCXXX Temodar, radiation these we to and NCI the methylated lung show combination NCI FDA granted ASCO prior patients. combination a with inhibiting expect the further in trial chemoradiation cancer repair whose patients in response These response refractory October advanced for We to presented the drug able excision setting, a chemoradiation malignant cell TRCXXX. inhibitor Based in therapy patients found cell non-small localized NCI a in glioblastoma to data our disease treatment. designation of in unresectable radiation XXXX into following these Data data cancer, XXXX advance XXXX chemotherapy compare was that patients glioblastoma. and notably now first-line development December on
ongoing checkpoint agent phase antibody, Our with CDXX X clinical-stage and inhibitor Phase is ASCO poster ongoing June. single dose-escalation TJXXXX presentation being study a the and trial Data an combination were third from for at in in Tecentriq. Meeting asset Virtual that a the XXXX evaluated is as accepted in
million. a are with development assets our developing long-term in to financials. and U.S. strategic evaluate them, clinical platform, agreements we an the time, whereby to license with I-Mab receive are this for option agreement will regulatory any independent We Per license new Scott From Biopharma us commercialization and drive terminate will we this the our responsible our allow expertise. At to key potentially like TJXXXX of with provide third Phase significant our in of agreement leverage platform TJXXXX $X to payment one development product I them, of China, the in that if the additional or to and value. for Taiwan. pipeline shareholder in U.S. on From two and to partnerships escalating We stage to add continue a Europe. continue of portions believe non-royalty TJXXXX collaboration clinical through we X, to payments the product the would update I-Mab I-Mab has Macau that CRO to of elects includes entitled business to will royalty to development completion development establish outside note a party of perspective, year region are order our
